Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
Globe Newswire (Tue, 3-Mar 9:05 AM ET)
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
Globe Newswire (Tue, 24-Feb 9:15 AM ET)
Globe Newswire (Fri, 20-Feb 8:50 AM ET)
Globe Newswire (Wed, 11-Feb 8:35 AM ET)
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
Globe Newswire (Tue, 3-Feb 9:00 AM ET)
Globe Newswire (Wed, 14-Jan 9:15 AM ET)
Globe Newswire (Fri, 9-Jan 8:55 AM ET)
Senti Biosciences Announces New Employment Inducement Grants
Globe Newswire (Thu, 18-Dec 5:30 PM ET)
Senti Bio’s SENTI-202 Wins Key FDA RMAT Designation: What 50% Response Rate Means for AML Therapy
Market Chameleon (Tue, 9-Dec 4:54 AM ET)
Market Chameleon (Tue, 9-Dec 2:54 AM ET)
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Senti Biosciences trades on the NASDAQ stock market under the symbol SNTI.
As of March 10, 2026, SNTI stock price climbed to $0.99 with 82,341 million shares trading.
SNTI has a beta of 1.28, meaning it tends to be more sensitive to market movements. SNTI has a correlation of 0.04 to the broad based SPY ETF.
SNTI has a market cap of $26.11 million. This is considered a Sub-Micro Cap stock.
Last quarter Senti Biosciences reported $0 in Revenue and -$.69 earnings per share. This fell short of revenue expectation by $-166,670 and missed earnings estimates by -$.11.
In the last 3 years, SNTI traded as high as $16.94 and as low as $.80.
The top ETF exchange traded funds that SNTI belongs to (by Net Assets): VTI, VXF, IWC.
SNTI has underperformed the market in the last year with a return of -71.8%, while the SPY ETF gained +18.8%. In the last 3 month period, SNTI fell short of the market, returning -35.5%, while SPY returned -0.6%. However, in the most recent 2 weeks SNTI has outperformed the stock market by returning +14.4%, while SPY returned -0.8%.
SNTI support price is $.93 and resistance is $1.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNTI shares will trade within this expected range on the day.
